[go: up one dir, main page]

AR086571A1 - METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN - Google Patents

METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN

Info

Publication number
AR086571A1
AR086571A1 ARP120101861A AR086571A1 AR 086571 A1 AR086571 A1 AR 086571A1 AR P120101861 A ARP120101861 A AR P120101861A AR 086571 A1 AR086571 A1 AR 086571A1
Authority
AR
Argentina
Prior art keywords
cpd
origin
methylation profile
methods
primary tumor
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Badosa Manel Esteller
Original Assignee
Fundacio Inst D & X2019 Investigacio Biomedica De Bellvitge Idibell
Fundacio Institucio Catalana De Recerca I Estudis Avancats
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacio Inst D & X2019 Investigacio Biomedica De Bellvitge Idibell, Fundacio Institucio Catalana De Recerca I Estudis Avancats filed Critical Fundacio Inst D & X2019 Investigacio Biomedica De Bellvitge Idibell
Priority to ARP120101861 priority Critical patent/AR086571A1/en
Publication of AR086571A1 publication Critical patent/AR086571A1/en

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se refiere a métodos y reactivos para la identificación del origen de un carcinoma de origen primario desconocido (CPD) basada en la determinación del perfil de metilación en el genoma del CPD. Se refiere también a métodos para seleccionar una terapia adecuada para un paciente que padece un CPD así como a métodos para la medicina personalizada de pacientes que padecen un CPD basándose en el uso de un tratamiento que sea adecuado para el tumor primario del que deriva el CPD. También se refiere a kits que comprenden reactivos adecuados para realizar los métodos anteriores así como a sistemas y programas informáticos que se pueden usar para implementar los métodos.Reivindicación 1: Un método para identificar el origen de un cáncer de origen primario desconocido (CPD) que comprende los pasos de: (i) determinar el perfil de metilación en una región seleccionada de un ADN aislado de dicho CPD y (ii) comparar el perfil de metilación de dicha región seleccionada con el perfil de metilación de la misma región en una muestra de ADN aislada de al menos un tumor primario en donde una identidad sustancial entre el perfil de metilación obtenido en el paso (i) y el perfil de metilación del tumor primario es indicativo de que el CPD deriva de dicho tumor primario.It refers to methods and reagents for the identification of the origin of a carcinoma of unknown primary origin (CPD) based on the determination of the methylation profile in the genome of the CPD. It also refers to methods for selecting a suitable therapy for a patient suffering from a CPD as well as methods for personalized medicine of patients suffering from a CPD based on the use of a treatment that is suitable for the primary tumor from which the CPD is derived. . It also refers to kits comprising suitable reagents for performing the above methods as well as systems and software that can be used to implement the methods. Claim 1: A method for identifying the origin of a cancer of unknown primary origin (CPD) that It comprises the steps of: (i) determining the methylation profile in a selected region of a DNA isolated from said CPD and (ii) comparing the methylation profile of said selected region with the methylation profile of the same region in a sample of DNA isolated from at least one primary tumor where a substantial identity between the methylation profile obtained in step (i) and the methylation profile of the primary tumor is indicative that the CPD derives from said primary tumor.

ARP120101861 2012-05-24 2012-05-24 METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN AR086571A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
ARP120101861 AR086571A1 (en) 2012-05-24 2012-05-24 METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ARP120101861 AR086571A1 (en) 2012-05-24 2012-05-24 METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN

Publications (1)

Publication Number Publication Date
AR086571A1 true AR086571A1 (en) 2014-01-08

Family

ID=50190871

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120101861 AR086571A1 (en) 2012-05-24 2012-05-24 METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN

Country Status (1)

Country Link
AR (1) AR086571A1 (en)

Similar Documents

Publication Publication Date Title
CO7151491A2 (en) Method for identifying the origin of a cancer of unknown primary origin
MX2017014736A (en) Therapeutic and diagnostic methods for cancer.
ECSP17025787A (en) USE OF FGFR MUTANT GENE PANELS IN IDENTIFYING CANCER PATIENTS WHO WILL RESPOND TO TREATMENT WITH AN FGFR INHIBITOR
MX2016011612A (en) DETERMINATION OF AGGRESSIVE, FORECAST AND RESPONSIVITY OF CANCER TO TREATMENT.
EA201400117A1 (en) METHODS AND NUCLEIC ACIDS FOR DETERMINATION OF THE PREDICTION IN CANCER PATIENTS
MX2018008421A (en) METHODS TO TREAT CANCER AND THE USE OF BIOMARKERS AS A PREDICATOR OF CLINICAL SENSITIVITY TO THERAPIES.
BR112018012374A2 (en) identification, manufacture and use of neoantigen
MX2023001945A (en) Compositions and methods for screening solid tumors.
MX2017013777A (en) METHOD FOR CANCER TREATMENT.
MX2017014381A (en) Therapeutic and diagnostic methods for cancer.
BR112017008082A2 (en) compositions and methods for detecting an rna virus
BR112014018331A8 (en) BIOMARKERS AND COMBINED THERAPIES USING ONCOLYTIC VIRUSES AND IMMUNOMODULATION
MX2015004610A (en) METHOD FOR DIAGNOSIS, FORECAST AND TREATMENT OF PROSTATE CANCER METASTASIS USING C-MAF.
BR112014011925A2 (en) human notch receptor mutations and their use
MX2022014633A (en) Methods for detecting norovirus.
CO2019011359A2 (en) System for predicting the prognosis and benefit of adjuvant chemotherapy for patients with stage II and III gastric cancer
MX2024003382A (en) COMPOSITIONS AND METHODS FOR DETECTING CIRCULATING TUMOUR DNA.
MX2017006075A (en) BIOMARKERS FOR THE PROGRESSION OF DISEASES IN MELANOMA.
GB2523211A8 (en) MCT protein inhibitor-related prognostic and therapeutic methods
ES2548299A1 (en) Signature of microRNA as an indicator of the risk of early recurrence in patients with breast cancer
BR112014023496A2 (en) c-raf mutants that confer resistance to raf inhibitors
AR086571A1 (en) METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN
PE20142434A1 (en) METHOD FOR THE IDENTIFICATION OF THE ORIGIN OF A CANCER OF UNKNOWN PRIMARY ORIGIN
MX2022003916A (en) USE OF SIMULTANEOUS MARKER DETECTION TO EVALUATE DIFFUSE GLIOMA AND RESPONSE TO TREATMENT.
BR102015015096A2 (en) in vitro detection method of thyroid cancer in a patient, in vitro method of differentiating thyroid cancer from normal thyroid tissue or benign thyroid lesions, use of a gene pool, method of obtaining data for treatment management cancer test, laboratory kit, and device for classifying a biological sample of thyroid gland as malignant or benign

Legal Events

Date Code Title Description
FB Suspension of granting procedure